ETON stock news · Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals is starting a new program to test ET-900 for treating infantile and epileptic spasms.

Aquestive Therapeutics, Inc. has made a big deal with Eton Pharmaceuticals to sell LIBERVANT for seizures in the U.S.

Eton gained exclusive U.S. sales rights to LIBERVANT, but must pay an upfront fee, possible milestones, and royalties. Approval and sales remain uncertain, so the filing does not show whether the rights will pay off.

Eton Pharmaceuticals has signed a big deal to sell LIBERVANT® in the U.S.

Eton gained exclusive U.S. rights to sell LIBERVANT, a treatment for seizure clusters. The added sales opportunity looks favorable, though sales depend on approvals and come with payments.

On Friday, significant upward movement was observed in the stocks of HeartFlow, Eton Pharmaceuticals, Nu Holdings, and several other major companies.

Reported better-than-expected quarterly financial results and issued FY26 revenue guidance above estimates, resulting in a 38.3% stock price increase.

Eton Pharmaceuticals stock jumps 22% in pre-market as 20 other shares show notable movement.

Eton Pharmaceuticals shares surged by over 22% in pre-market trading following the release of strong second-quarter financial results that exceeded analyst expectations, along with optimistic revenue guidance for FY26. This significant earnings beat is expected to attract investor interest and drive further trading activity.

Eton Pharmaceuticals Q2 2026 Earnings Conference: Full Transcript Available.

Eton Pharmaceuticals' Q2 2026 earnings call revealed a record revenue of $37.6 million, a 99% increase from the previous year, and an upward revision of its revenue guidance for the year. This strong performance is attributed to the successful relaunch of Hemangiol and strategic acquisitions, positioning the company favorably in the biotech sector.